Corticosteroids in brain cancer patients: benefits and pitfalls

Glucocorticoids have been used for decades in the treatment of brain tumor patients and belong to the most powerful class of agents in reducing tumor-associated edema and minimizing side effects and the risk of encephalopathy in patients undergoing radiation therapy. Unfortunately, corticosteroids are associated with numerous and well-characterized adverse effects, constituting a major challenge in patients requiring long-term application of corticosteroids. Novel anti-angiogenic agents, such as bevacizumab (Avastin®), which have been increasingly used in cancer patients, are associated with significant steroid-sparing effects, allowing neuro-oncologists to reduce the overall use of corticosteroids in patients with progressive malignant brain tumors. Recent experimental studies have revealed novel insights into the mechanisms and effects of corticosteroids in cancer patients, including modulation of tumor biology, angiogenesis and steroid-associated neurotoxicity. This article summarizes current concepts of using corticosteroids in brain cancer patients and highlights potential pitfalls in their effects on both tumor and neural progenitor cells.

[1]  M. Weller,et al.  Steroids in neurooncology: actions, indications, side-effects. , 2010, Current opinion in neurology.

[2]  C. Pui,et al.  Glucocorticoid use in acute lymphoblastic leukaemia. , 2010, The Lancet. Oncology.

[3]  D. Furst,et al.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis , 2010, Arthritis care & research.

[4]  J. Tuckermann,et al.  The role of the glucocorticoid receptor in inflammation and immunity , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  A. Carpentier,et al.  Steroid requirements during radiotherapy for malignant gliomas , 2010, Journal of Neuro-Oncology.

[6]  G. Chrousos,et al.  The human glucocorticoid receptor: Molecular basis of biologic function , 2010, Steroids.

[7]  D. Kondziolka,et al.  The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[8]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Patrick Y Wen,et al.  End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Jain,et al.  VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer , 2009, Nature Reviews Clinical Oncology.

[11]  C. Förster,et al.  Glucocorticoids Increase VE-Cadherin Expression and Cause Cytoskeletal Rearrangements in Murine Brain Endothelial cEND Cells , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  G. Pond,et al.  The use and toxicity of steroids in the management of patients with brain metastases , 2008, Supportive Care in Cancer.

[13]  A. Storch,et al.  Dexamethasone blocks astroglial differentiation from neural precursor cells , 2006, Neuroreport.

[14]  J. Haorah,et al.  Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions , 2006, Journal of Neuroimmune Pharmacology.

[15]  P. Wen,et al.  Medical management of patients with brain tumors , 2006, Journal of Neuro-Oncology.

[16]  M. Sundberg,et al.  Glucocorticoid Hormones Decrease Proliferation of Embryonic Neural Stem Cells through Ubiquitin-Mediated Degradation of Cyclin D1 , 2006, The Journal of Neuroscience.

[17]  G. Goozée,et al.  A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[18]  H. Reichardt,et al.  Glucocorticoids in T cell apoptosis and function , 2005, Cellular and Molecular Life Sciences.

[19]  P. Barnes.  Molecular mechanisms and cellular effects of glucocorticosteroids. , 2005, Immunology and allergy clinics of North America.

[20]  C. Förster,et al.  Occludin as direct target for glucocorticoid‐induced improvement of blood–brain barrier properties in a murine in vitro system , 2005, The Journal of physiology.

[21]  A. Lipton.  New therapeutic agents for the treatment of bone diseases , 2005, Expert opinion on biological therapy.

[22]  Rolando F. Del Maestro,et al.  Effect of steroids on iopamidol blood-brain transfer constant and plasma volume in brain tumors measured with X-ray computed tomography , 2005, Journal of Neuro-Oncology.

[23]  I. Adcock,et al.  [Molecular mechanisms of glucocorticoids]. , 2005, Archivos de bronconeumologia.

[24]  J. Owczarek,et al.  Drug-induced myopathies. An overview of the possible mechanisms. , 2005, Pharmacological reports : PR.

[25]  M. C. Papadopoulos,et al.  Molecular mechanisms of brain tumor edema , 2004, Neuroscience.

[26]  N. Banik,et al.  Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities , 2004, Molecular Cancer.

[27]  H. Son,et al.  Dexamethasone inhibits proliferation of adult hippocampal neurogenesis in vivo and in vitro , 2004, Brain Research.

[28]  H. Son,et al.  Differential effects of corticosterone and dexamethasone on hippocampal neurogenesis in vitro. , 2004, Biochemical and biophysical research communications.

[29]  N. Nathoo,et al.  The eicosanoid cascade: possible role in gliomas and meningiomas , 2003, Journal of clinical pathology.

[30]  K. Plate,et al.  VEGF in Brain Tumors , 2000, Journal of Neuro-Oncology.

[31]  D. Schiff.  Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features , 1996, Journal of Neuro-Oncology.

[32]  H. Knüpfer,et al.  Time-dependent Inhibition of Glioblastoma Cell Proliferation by Dexamethasone , 2004, Journal of Neuro-Oncology.

[33]  S. Grossman,et al.  Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. , 2003, Cancer treatment reviews.

[34]  J. Cidlowski,et al.  Molecular mechanisms of glucocorticoid action and resistance , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  S. Rüegg.  Dexamethasone/phenytoin interactions: neurooncological concerns. , 2002, Swiss medical weekly.

[36]  M. Perretti,et al.  Regulation of Leukocyte‐Endothelial Interactions by Glucocorticoids , 2002, Annals of the New York Academy of Sciences.

[37]  K. Carson,et al.  A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. , 2002, Neuro-oncology.

[38]  K. Chihara,et al.  Insulin-like growth factor 1 inhibits glucocorticoid-induced glutamine synthetase activity in cultured L6 rat skeletal muscle cells , 2001, Neuroscience Letters.

[39]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .

[40]  D. Franchimont,et al.  Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes1 , 2000, The Journal of Immunology.

[41]  H. Cohen,et al.  Cognitive decline in patients with Cushing's syndrome , 2000, Journal of the International Neuropsychological Society.

[42]  M. Westphal,et al.  Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas , 1999, International Journal of Developmental Neuroscience.

[43]  C. Riccardi,et al.  Dexamethasone-induced thymocyte apoptosis: apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C, acidic sphingomyelinase, and caspases. , 1999, Blood.

[44]  T. Hander,et al.  A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  E. Papavassiliou,et al.  Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. , 1996, The Journal of clinical investigation.

[46]  L. Deangelis,et al.  Medical management of cerebral metastases. , 1996, Neurosurgery clinics of North America.

[47]  R. Blasberg,et al.  Corticotropin-releasing factor decreases vasogenic brain edema. , 1996, Cancer research.

[48]  Koehler Pj.  Use of corticosteroids in neuro-oncology. , 1995 .

[49]  P. Koehler.  Use of corticosteroids in neuro-oncology. , 1995, Anti-cancer drugs.

[50]  K. Whyte,et al.  Discrimination against people with HIVinfection and AIDS , 1994, BMJ.

[51]  W. van Putten,et al.  Dose‐effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors , 1994, Neurology.

[52]  K. Sepkowitz,et al.  Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. , 1992, JAMA.

[53]  B. Strom,et al.  The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. , 1991, The American journal of medicine.

[54]  S. Soong,et al.  Steroid‐induced weakness in patients with primary brain tumors , 1991, Neurology.

[55]  J. G. Quintrec,et al.  Drug-induced myopathies. , 1991, Bailliere's clinical rheumatology.

[56]  J. Henson,et al.  Pneumocystis carinii pneumonia in patients with primary brain tumors. , 1991, Archives of neurology.

[57]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Ahmed Ar,et al.  Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. , 1989 .

[59]  A. Ahmed,et al.  Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. , 1989, Annals of allergy.

[60]  M. Sogin,et al.  Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the Fungi , 1988, Nature.

[61]  N. Vick.  Steroid toxicity. , 1988, Journal of neuro-oncology.

[62]  R. Ruff,et al.  Endocrine myopathies. , 1988, Neurologic clinics.

[63]  J. Best,et al.  BRAIN WATER MEASURED BY MAGNETIC RESONANCE IMAGING Correlation with Direct Estimation and Changes After Mannitol and Dexamethasone , 1987, The Lancet.

[64]  M. Frame,et al.  Phenotypic modification of human glioma and non-small cell lung carcinoma by glucocorticoids and other agents. , 1986, Anticancer research.

[65]  C. Miller,et al.  Steroid-induced remission in primary malignant lymphoma of the central nervous system. , 1986, Surgical neurology.

[66]  D. Goldspink,et al.  A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle , 1986, Muscle & nerve.

[67]  E. Hedley‐Whyte,et al.  Effect of dexamethasone on blood-brain barrier in the normal mouse. , 1986, Annals of neurology.

[68]  T. Poynard,et al.  Adrenocorticosteroid administration and peptic ulcer: a critical analysis. , 1985, Journal of chronic diseases.

[69]  M. Eadie,et al.  Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[70]  D. Ettinger,et al.  Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. , 1984, The New England journal of medicine.

[71]  H. M. Bartkowski.  Peritumoral edema. , 1984, Progress in experimental tumor research.

[72]  R. Layzer.  Neuromuscular manifestations of systemic disease , 1984 .

[73]  M. Newmark,et al.  Drug Spotlight Program: The Use of Antiepileptic Drugs , 1979 .

[74]  M. Newmark,et al.  The use of antiepileptic drugs. , 1979, Annals of internal medicine.

[75]  J. Miller,et al.  Methylprednisolone treatment in patients with brain tumors. , 1977, Neurosurgery.

[76]  R. Moskowitz,et al.  Steroid myopathy in connective tissue disease. , 1976, The American journal of medicine.

[77]  H O Conn,et al.  Nonassociation of adrenocorticosteroid therapy and peptic ulcer. , 1976, The New England journal of medicine.

[78]  J. Miller,et al.  Effects of mannitol and steroid therapy on intracranial volume-pressure relationships in patients. , 1975, Journal of neurosurgery.

[79]  P. Gutin.  Corticosteroid therapy in patients with cerebral tumors: benefits, mechanisms, problems, practicalities. , 1975, Seminars in oncology.

[80]  C. Koski,et al.  Oxidative metabolism of skeletal muscle in steroid atrophy. , 1974, Archives of neurology.

[81]  E. Werk,et al.  Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. , 1972, The Journal of clinical endocrinology and metabolism.

[82]  E. Werk,et al.  Effect of diphenylhydantoin on cortisol kinetics in humans. , 1971, The Journal of pharmacology and experimental therapeutics.

[83]  J. Melby,et al.  Use of dexamethasone in treatment of cerebral edema associated with brain tumors. , 1961, The Journal-lancet.

[84]  S. Taylor,et al.  Treatment of cerebral metastases from breast carcinoma with prednisolone. , 1957, Journal of the American Medical Association.

[85]  R. Mclaurin,et al.  Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. , 1952, The New England journal of medicine.